<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">The first anti-HIV drugs to be clinically associated with lipodystrophy were protease inhibitors (PIs)
 <sup>
  <xref ref-type="bibr" rid="CR15">15</xref>
 </sup>, and this relationship was later confirmed by 
 <italic>in vitro</italic> studies
 <sup>
  <xref ref-type="bibr" rid="CR16">16</xref>,
  <xref ref-type="bibr" rid="CR17">17</xref>
 </sup>. The treatment duration with NAs, especially thymidine nucleotides, was subsequently observed to be associated with the onset of lipodystrophy and lactic acidosis
 <sup>
  <xref ref-type="bibr" rid="CR17">17</xref>
 </sup>, mainly as a consequence of inhibition of DNA polymerase-Î³ in mitochondria
 <sup>
  <xref ref-type="bibr" rid="CR18">18</xref>,
  <xref ref-type="bibr" rid="CR19">19</xref>
 </sup>. BSCs have also been associated to the onset of metabolic syndrome and increased cardiovascular risk in HIV-infected patients receiving HAART
 <sup>
  <xref ref-type="bibr" rid="CR20">20</xref>,
  <xref ref-type="bibr" rid="CR21">21</xref>
 </sup>.
</p>
